Relationship Between MMP-1, MMP-9, TIMP-1, IL-6 and Risk Factors, Clinical Presentation, Extent and Severity of Atherosclerotic Coronary Artery Disease
- PMID: 21772929
- PMCID: PMC3136999
- DOI: 10.2174/1874192401105010110
Relationship Between MMP-1, MMP-9, TIMP-1, IL-6 and Risk Factors, Clinical Presentation, Extent and Severity of Atherosclerotic Coronary Artery Disease
Abstract
Background: Matrix metalloproteinases (MMPs) and Tissue Inhibitor of Matrix Metalloproteinases (TIMPs) may be associated with atherogenesis and plaque rupture. We evaluated the relationship between MMP-1, MMP-9, TIMP-1 and IL-6 levels and risk factors, presentation, extent and severity of atherosclerotic coronary artery disease (CAD).
Methods: Consecutive patients who underwent coronary angiography were randomly included. The serum concentrations of MMP-1, MMP-9, TIMP-1 and IL-6 were analyzed with ELISA method in 134 patients. Participants were divided into 5 groups; stable angina pectoris (SAP; n= 34), unstable angina pectoris (USAP; n=29), non-ST elevation myocardial infarction (NSTEMI; n=16), acute ST elevation myocardial infarction (STEMI; n=25) and controls (n=30). Coronary angiographic Gensini score was calculated.
Results: MMP-1 levels were higher in STEMI and NSTEMI groups compared with USAP, SAP and control groups (STEMI vs USAP p=0.005; STEMI vs SAP p=0.001; STEMI vs control p<0.001; NSTEMI vs USAP p=0.02; NSTEMI vs SAP p=0.027; NSTEMI vs control p<0.001). In STEMI group, MMP-9 levels were higher than USAP and control groups (p=0.002; p<0,001). TIMP-1 levels were not significantly different within all 5 groups. MMP-1 levels were found to be elevated in diabetic patients (p=0.020); whereas MMP-9 levels were higher in smokers (p=0.043). Higher MMP-1, MMP-9 and IL-6 levels were correlated with severe Left Anterior Descending artery (LAD) stenosis and higher angiographic Gensini Score (for severe LAD stenosis; r = 0.671, 0.363, 0.509 p<0.001; for Gensini score; r = 0.717, 0.371, 0.578 p<0.001).
Conclusions: Serum levels of MMP-1, MMP-9, and IL-6 are elevated in patients with CAD; more so in acute coronary syndromes. MMP-1, MMP-9 and IL-6 are associated with more extensive and severe CAD (as represented by Gensini score).
Keywords: Gensini score.; Interleukin-6; Matrix metalloproteinase; coronary artery disease.
Figures
Similar articles
-
Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.Am J Cardiol. 2010 Feb 15;105(4):429-34. doi: 10.1016/j.amjcard.2009.10.013. Epub 2010 Jan 5. Am J Cardiol. 2010. PMID: 20152234
-
Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease.PLoS One. 2019 Aug 6;14(8):e0220841. doi: 10.1371/journal.pone.0220841. eCollection 2019. PLoS One. 2019. PMID: 31387110 Free PMC article.
-
Ischemic Modified Albumin Predicts Critical Coronary Artery Disease in Unstable Angina Pectoris and Non-ST-Elevation Myocardial Infarction.J Clin Med Res. 2018 Jul;10(7):570-575. doi: 10.14740/jocmr3417w. Epub 2018 Jun 4. J Clin Med Res. 2018. PMID: 29904441 Free PMC article.
-
API expert consensus document on management of ischemic heart disease.J Assoc Physicians India. 2006 Jun;54:469-80. J Assoc Physicians India. 2006. PMID: 16909697 Review.
-
Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis.Eur Heart J Cardiovasc Imaging. 2016 Oct;17(10):1128-37. doi: 10.1093/ehjci/jev283. Epub 2015 Oct 27. Eur Heart J Cardiovasc Imaging. 2016. PMID: 26508517 Review.
Cited by
-
Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention.BMC Cardiovasc Disord. 2023 Nov 28;23(1):586. doi: 10.1186/s12872-023-03570-8. BMC Cardiovasc Disord. 2023. PMID: 38017432 Free PMC article.
-
Prolonged Door-to-Balloon Time Leads to Endothelial Glycocalyx Damage and Endothelial Dysfunction in Patients with ST-Elevation Myocardial Infarction.Biomedicines. 2023 Oct 29;11(11):2924. doi: 10.3390/biomedicines11112924. Biomedicines. 2023. PMID: 38001925 Free PMC article.
-
2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome.Acta Cardiol Sin. 2023 Jan;39(1):4-96. doi: 10.6515/ACS.202301_39(1).20221103A. Acta Cardiol Sin. 2023. PMID: 36685161 Free PMC article.
-
Extracellular Matrix Remodeling Biomarkers in Coronary Artery Disease.Curr Top Med Chem. 2022;22(28):2355-2367. doi: 10.2174/1568026623666221024091758. Curr Top Med Chem. 2022. PMID: 36284400
-
S100A9 is a functional effector of infarct wall thinning after myocardial infarction.Am J Physiol Heart Circ Physiol. 2022 Feb 1;322(2):H145-H155. doi: 10.1152/ajpheart.00475.2021. Epub 2021 Dec 10. Am J Physiol Heart Circ Physiol. 2022. PMID: 34890276 Free PMC article.
References
-
- Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Ip S. The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med. 2010;153:387–95. - PubMed
-
- Arakaki PA, Marques MR, Santos MCLG. MMP-1 polymorphism and its relationship to pathological processes. J Biosci. 2009;34:313–20. - PubMed
-
- Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73. - PubMed
-
- Choudhary S, Higgins CL, Chen IY, et al. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissue. Arterioscler Thromb Vasc Biol. 2006;26:2351–58. - PubMed
-
- Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37:235–9. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous